ライフサイエンスコーパス: HCV antibody

1 HIV-1-positive women who tested negative for HCV antibody.

2 NA was detected an average of 31 days before HCV antibody.

3 to 2022, 44.6% of the cohort were tested for HCV antibody.

4 ts were screened for the presence of an anti-HCV antibody.

5 care workers tested negative for HCV RNA and HCV antibodies.

6 creases the efficacy of broadly neutralizing HCV antibodies.

7 pid diagnostic tests (RDTs) for detection of HCV antibodies.

8 with significantly different efficiency with HCV antibodies.

9 investigation who were seropositive for anti-HCV antibodies.

10 ved between viremia and the presence of anti-HCV antibodies.

11 ber 9, 2020, underwent testing for HBsAg and HCV antibodies.

12 itive vs. negative), determined by detecting HCV antibodies.

13 ides mimicking this structure to elicit anti-HCV antibodies.

14 differed by age (50 vs. 42 years), positive HCV antibody (11 vs. 2%) and death from stroke (51 vs. 4

15 Of 2514 women, 97 (3.9%) had anti-HCV antibodies, 54 (2.1%) were viremic and of those, 52

16 cumulative 974,817 adults were screened for HCV antibodies, 86,624 persons tested positive, of which

17 cumulative 974 817 adults were screened for HCV antibodies; 86 624 persons tested positive, of whom

18 nts transplanted during 1996 to 2001 who had HCV antibodies (Ab) measured before transplantation.

19 This study estimated HCV antibody (Ab) prevalence in Qatar and examined assoc

20 screened for HCV and 64 (6%) had a positive HCV antibody (Ab) result at initial screening.

21 ibe early experience with integrated opt-out HCV antibody (Ab) screening of medically stable baby boo

22 through the HCV continuum of care (CoC) from HCV antibody (Ab) screening, HCV-RNA confirmation, engag

23 screening with liver function tests (LFTs), HCV antibody (Ab) screening, or HCV RNA screening in var

24 a propensity-matched cohort of recipients of HCV antibody (Ab)(+) kidneys versus Ab(-) kidneys.

25 The testing pathway includes HCV antibody (Ab), automatic HCV RNA for Ab-positive pat

26 nds and associations with hepatitis C virus (HCV) antibody (Ab) prevalence in the Middle East and Nor

27 We compared recipients of a kidney from an HCV antibody- (Ab-)/nucleic acid test- (NAT-), HCV Ab+/N

28 prevalence of IDU, HIV antibody, HBsAg, and HCV antibody among PWID were selected and, where multipl

29 ed civilian adults in the United States with HCV antibodies and 2.1 million with HCV RNA and an estim

30 induced by DNA immunization to generate anti-HCV antibodies and anticore CTLs.

31 sion could be specifically inhibited by anti-HCV antibodies and by at least one peptide.

32 ort study in Georgia among adults tested for HCV antibodies and followed longitudinally for the devel

33 n at Cairo University were screened for anti-HCV antibodies and HCV RNA, and viremic women were teste

34 with HCV-infected siblings were screened for HCV antibodies and HCV RNA.

35 re infected persons than routine testing for HCV antibodies and liver enzymes.

36 ents had HCV RNA (chronic infection), 91 had HCV antibodies and no HCV RNA (cleared infection), and 1

37 Main outcomes included anti-HCV antibody and active HCV infection (HCV-RNA+) prevale

38 At a minimum, HCV antibody and alanine aminotransferase testing should

39 During the pre-COVID-19 period, monthly HCV antibody and genotype tests decreased slightly where

40 of hepatitis C virus (HCV) diagnostic tests (HCV antibody and HCV nucleic acid) from class III to cla

41 HCV antibody and HCV RNA prevalence were 58.8% (95% conf

42 in women with or without HIV-1 infection, by HCV antibody and HCV RNA status.

43 women were grouped on the basis of positive HCV antibody and HCV RNA tests.

44 calibrated to San Francisco data, including HCV antibody and HIV prevalence among ever MSM-IDU.

45 rom injection drug users (IDUs) persistently HCV antibody and RNA negative despite high-risk behavior

46 monstrated across 3 settings that the use of HCV antibody and RNA POCT increased testing rates, treat

47 of this study was to evaluate the effect of HCV antibody and RNA point-of-care testing (POCT) on tes

48 positive but RNA negative, and 112 who were HCV antibody and RNA positive.

49 Given high HCV antibody and RNA prevalence, integrating HCV care in

50 f a mathematical model and based on maternal HCV antibody and viremia.

51 infection was defined by first positive anti-HCV antibody and/or HCV RNA within 6 months of enrollmen

52 tis C virus (HCV; based on detection of anti-HCV antibody), and hepatitis B virus (HBV; based on dete

53 s among women who tested positive for HIV-1, HCV antibody, and HCV RNA, compared with HIV-1-positive

54 lood samples were tested for the presence of HCV antibodies (anti-HCV), HBV surface antigen (HBsAg),

55 er, Women and Infants Transmission Study had HCV antibody (anti-HCV by second-generation ELISA) and H

56 a serosurvey showed the adult prevalence of HCV antibody (anti-HCV) and HCV RNA to be 7.7% and 5.4%,

57 All practices tested patients for anti-HCV antibody (anti-HCV) and HCV RNA.

58 urveys had data on diabetes status and serum HCV antibody (anti-HCV) or HCV RNA.

59 rs, Chembio, OraSure, and MedMira, submitted HCV antibody (anti-HCV) rapid screening assays to the CD

60 se Control and Prevention in 1998 recommends HCV antibody (anti-HCV) testing for persons with specifi

61 y assigned to receive a one-time offering of HCV antibody (anti-HCV) testing via one of three indepen

62 ase, we identified all subjects initiated on HCV antibody (anti-HCV) therapy from 2001 to 2014, and a

63 ed with incident HCV in MSM since 1984, 5310 HCV antibody (anti-HCV)-negative MSM in the Multicenter

64 2-1993, the prevalence of hepatitis C virus (HCV) antibodies (anti-HCV) among US blood donors was 0.3

65 sociated with past or present HCV infection (HCV antibody [anti-HCV] positive) among young (<=35 year

66 t EIA were 97.78, 93.54, and 97.66% for anti-HCV antibodies, anti-HBsAg antibodies, and HBsAg, respec

67 Thus, we have designed an HCV antibody assay that employs a conformational protein

68 Seronegative participants were tested for HCV antibodies at baseline, at 6 months, and at 12 month

69 erase (ALT) elevations and seroconversion to HCV antibodies at week 10 p.i.

70 atitis C virus (HCV) viremia be screened for HCV antibody at age 18 months and, if positive, referred

71 er 31, 2019, and 1,849,820 adults tested for HCV antibodies between January 1, 2015 and September 30,

72 nreliable, with two patients having negative HCV antibody but a positive HCV RNA at diagnosis.

73 strates the principle that neutralizing anti-HCV antibodies can be induced by epitope-based, engineer

74 viruses, likely due to synergy between anti-HCV antibodies derived from different plasma donors, and

75 nic system, 3783 patients with positive anti-HCV antibody documentation were identified.

76 bitory activity of broadly neutralizing anti-HCV antibodies elicited by candidate vaccines.

77 (3) were significantly associated with lower HCV antibody end-point titers.

78 t hepatitis B surface antigen in three (6%), HCV antibody (enzyme-linked immunosorbent assay II suppl

79 HCV POCT was performed using SD Bioline HCV antibody fingerstick test and a reflexive Xpert HCV

80 tronic health records of patients tested for HCV antibody from 2012 to 2016 and calculated the percen

81 Prevalence of hepatitis C virus (HCV) antibody has been reported in Mexican Americans, bu

82 A blood sample was screened for HCV antibody (HCV AB) using the OraQuick HCV Rapid Antib

83 C virus (HCV) viremia, involving testing for HCV antibody (HCVAb) followed by a nucleic acid test (NA

84 (RVF) immunotechnology for detection of anti-HCV antibodies in an effort to extend the capabilities o

85 volume modification more accurately detects HCV antibodies in DBS whole blood samples with 100% sens

86 ised 7,005 and 21,729 persons diagnosed with HCV antibodies in Denmark and Scotland, respectively.

87 Enzyme immunoassay detection of anti-HCV antibodies in specimens from DBS was reliable after

88 tients who had prior tests for positive anti-HCV antibody in 2010-2018 in our hospital were enrolled

89 Positive HCV antibody in recipients did not adversely affect the

90 From four of these patients, we isolated 310 HCV antibodies, including neutralizing antibodies with e

91 alence was estimated by the presence of anti-HCV antibodies incorporating respondent-driven sampling

92 These results suggest that profiling anti-HCV antibody is useful for monitoring HCV therapy, espec

93 IV infection on B cell function, we compared HCV antibody levels and specificities in 29 HCV-infected

94 HCV antibody levels were unreliable, with two patients h

95 ds that simultaneously estimated the time to HCV-antibody loss in uninfected infants and the diagnost

96 The patient was HCV antibody negative and HCV RNA negative by PCR of the

97 cipients were HCV nucleic acid test and anti-HCV antibody negative at the time of transplant and rece

98 We included GBM who tested HCV antibody negative at their first test and had >=1 su

99 There were 148 women who were HCV antibody negative, 34 who were HCV antibody positive

100 Twenty-eight percent were HCV antibody negative/RNA positive at the time of acute

101 50% of uninfected children became HCV-antibody negative by 8 months and 95% by 13 months.

102 HCV-antibody negative recipients of HCV-antibody positiv

103 ic blood donors from 1991 to 2002 and 10,259 HCV antibody-negative (HCV-) donors matched for year of

104 Patients who were HCV antibody-negative at baseline were followed up after

105 lanted from HCV antibody-positive (HCV+) vs. HCV antibody-negative donors.

106 with a history of illicit drug use who were HCV antibody-negative in 1988 were followed semiannually

107 None of the 233 HCV antibody-negative patients were shown to be viremic

108 a lower survival estimate when compared with HCV antibody-negative recipients in the past era (55.3%

109 HCV RNA was detected in 38% of HCV antibody-negative subjects by the whole-blood-based

110 n (HCV RNA-positive) and 1,941 HCV-negative (HCV antibody-negative) controls.

111 NA measurements and HCV treatment, as either HCV antibody-negative; spontaneously resolved HCV; chron

112 prior hepatitis C treatment were tested for HCV antibodies, of which 1,665 (18%) had a positive resu

113 63 PEH (13.4%) had test results positive for HCV antibodies, of whom 172 (47.4%) had test results pos

114 /HTLV-II(+), and HIV(-)/HTLV-II(-)), 376 had HCV antibodies, of whom 305 had detectable HCV load.

115 We performed both G2 and G3 EIAs for anti-HCV antibodies on 1,134 serum samples collected during t

116 Blood donors who tested positive for HCV antibodies on enzyme immunoassay were classified acc

117 V infection assessed by the presence of anti-HCV antibodies or HCV RNA.

118 Graft utilization from positive HCV antibody or nucleic acid amplification test-positive

119 le if they had evidence of an HCV infection (HCV antibody or RNA positive test) followed by spontaneo

120 uals prescribed OAT, 44% (6817/15382) had an HCV antibody or RNA test after their first OAT prescript

121 00 IU/L were followed up within 12 months by HCV antibody or RNA testing.

122 ated with screening for HCV infection (using HCV antibody or RNA), performed temporal analyses to ass

123 were significant increases in month-to-month HCV antibody (P < .001), RNA (P = .035), and genotype te

124 ened for hepatitis C virus (HCV), 180 tested HCV antibody positive (34%), and 108 were HCV-ribonuclei

125 ia whose HLA-identical donor was found to be HCV antibody positive and HCV RNA positive by polymerase

126 who were HCV antibody negative, 34 who were HCV antibody positive but RNA negative, and 112 who were

127 egative recipients who received kidneys from HCV antibody positive donors (D-HCV) (n=48); and (3) HCV

128 ups of adult renal allograft recipients: (1) HCV antibody positive recipients (R-HCV) (n=32); (2) HCV

129 nd March 2017, 402 participants who were HIV/HCV antibody positive were enrolled (95% male [80% gay a

130 In the 5777 people who were HCV antibody positive, 2086 (34.4%) reported harmful or

131 393 (12%) partner participants were HCV antibody positive, 213 (54%) of whom had viraemia an

132 f the 5777 people who inject drugs that were HCV antibody positive, 440 (5.5%) were aware of their st

133 tners was 17 (IQR: 6, 50) and 246 (19%) were HCV antibody positive.

134 terquartile range, 6-50), and 246 (19%) were HCV antibody positive.

135 Of 4713 patients, 652 (13.8%) were HCV antibody positive.

136 nty-six of the 1000 (7.6%) participants were HCV antibody positive; none were confirmed by detection

137 HCV-antibody negative recipients of HCV-antibody positive hearts were identified from Januar

138 infection in heart transplant recipients of HCV-antibody positive organs is not known.

139 At baseline, 521 patients (45.4%) were HCV-antibody positive, 85 (7.4%) were hepatitis B surfac

140 D are living with HIV, 52.3% (42.4-62.1) are HCV-antibody positive, and 9.0% (5.1-13.2) are HBV surfa

141 -2.39), HCV RNA testing among those who were HCV antibody-positive (2 studies; OR, 1.83; 95% CI, 1.27

142 tes between those who were transplanted from HCV antibody-positive (HCV+) vs. HCV antibody-negative d

143 ,259 recombinant immunoblot assay-confirmed, HCV antibody-positive (HCV+), allogeneic blood donors fr

144 ximately 4.1 (3.4-4.9) million persons, were HCV antibody-positive (indicating past or current infect

145 We studied HCV antibody-positive adults with HIV in the EuroSIDA st

146 The prevalence of HCV antibody-positive and chronic HCV infection at acces

147 isk of vertical HCV infection to children of HCV antibody-positive and RNA-positive women was 5.8% (9

148 of risk were generated for children born to HCV antibody-positive and viremic women, aged >/=18 mont

149 Participants who were HCV antibody-positive at enrolment and those with HCV an

150 797 pregnancies in 16 888 people who tested HCV antibody-positive between 1999 and 2021.

151 Patients receiving HCV antibody-positive donor hearts without detectable ci

152 Additionally, there were 2,635 LTs using HCV antibody-positive donors (DAb(+) ): 2,378 DAb(+) /R(

153 Organ use from HCV antibody-positive donors (n = 371, 1.5%) was concent

154 een eradicated or persists at a low level in HCV antibody-positive HCV RNA-negative individuals.

155 HCV antibody-positive individuals were 3-fold more likel

156 Of 155 singleton infants born to HCV antibody-positive mothers, 13 (8.4%) were HCV infect

157 ation of liver grafts from DCD HCV - and DCD HCV antibody-positive nucleic acid test negative donors.

158 iver transplant recipients transplanted with HCV antibody-positive organs.

159 Between July 2014 and March 2017, 402 HIV/HCV antibody-positive participants were enrolled (95% ma

160 We analyzed 36 liver samples from HCV antibody-positive patients (30 from patients with ch

161 s based on viral load reflex testing of anti-HCV antibody-positive patients (known as one-step diagno

162 HCV RNA was detected in 85% of HCV antibody-positive patients by the whole-blood method

163 Conclusion: Nonviremic HCV antibody-positive patients have a liver biopsy that

164 Sixty-two percent of respondents would refer HCV antibody-positive patients with abnormal transaminas

165 approach to the management of 2 hypothetical HCV antibody-positive patients, 1 with elevated and the

166 n with HCV RNA and an estimated 0.38 million HCV antibody-positive persons and 0.25 million HCV RNA-p

167 HCV-specific CD4+ T-helper-cell response in HCV antibody-positive persons who lack detectable plasma

168 HCV antibody-positive recipients (n = 520, 2.1%) had sta

169 eliability of G2 and G3 EIAs to confirm anti-HCV antibody-positive results.

170 We analyze 692 HCV antibody-positive specimens collected from rural com

171 The five HCV antibody-positive subjects who were negative by whol

172 with a history of injection drug use and an HCV antibody-positive test result during follow-up.

173 One hundred seventy-two HCV antibody-positive, serum HCV RNA-negative patients u

174 negative recipients of liver allografts from HCV antibody-positive/NAT-negative (Ab + /NAT - ) donors

175 an age of 56 +/- 11 SD) received hearts from HCV-antibody-positive donors.

176 HCV antibody positivity was high in MSM with HIV (20%) a

177 HCV antibody positivity was high in MSM with HIV (20%) a

178 2.16, 95% CI 1.40-3.33] were associated with HCV antibody positivity.

179 ssion was used to evaluate associations with HCV antibody positivity.

180 using (2.16; 1.40-3.33) were associated with HCV antibody positivity.

181 past estimates based on similar methodology, HCV antibody prevalence may have increased, while RNA pr

182 All reports of anti-HCV antibody prevalence were much higher than any single

183 702 IDUs aged 18-30 years were screened for HCV antibodies; prevalence was 27%.

184 est that HCV infection could cause some anti-HCV-antibody-producing hybridoma B cells to make less-pr

185 stern blot analyses with anti-c-Myc and anti-HCV antibodies provided positive identification of both

186 Patients who screened HCV antibody reactive between 1 May and 31 October 2014

187 Of the 532 HCV antibody-reactive patients, 435 completed viral load

188 ection, and screening identified 532 (14.4%) HCV antibody-reactive patients.

189 CV antibody screening and HCV RNA testing of HCV antibody-reactive specimens is recommended for detec

190 Automatic reflexive HCV RNA testing of HCV antibody-reactive specimens was identified as a gap

191 ent of respondents would retest patients for HCV antibody, regardless of risk factors and transaminas

192 ne the effect of HIV coinfection on the anti-HCV antibody response, we measured anti-HCV envelope bin

193 ends in HCV RNA testing following a positive HCV antibody result among persons in 4 large healthcare

194 infection; one-third of them had a negative HCV antibody result at the time of HCV RNA positivity.

195 Of the 1287 (99%) MSM with HCV antibody results, median age was 41, 69% were Black,

196 Among the 1287 (99%) of the MSM with HCV antibody results, the median age was 41, 69% were bl

197 We obtained monthly state-level volumes of HCV antibody, RNA and genotype testing, and HCV treatmen

198 rus (HCV) infection requires both a positive HCV antibody screen and confirmatory nucleic acid testin

199 cted to full clinical evaluation, ELISA anti-HCV antibodies screening, parasitological examination fo

200 ites States a 2-step algorithm consisting of HCV antibody screening and HCV RNA testing of HCV antibo

201 between 2000 and 2011, 14 534 (85%) received HCV antibody screening within 3 months of enrolling in c

202 ntibody-positive at enrolment and those with HCV antibody seroconversion during follow-up (1996 to 20

203 ferase > 10 x upper limit of normal) or anti-HCV antibody seroconversion within 18 months.

204 s found a relationship between positive anti-HCV antibody serologic prevalence and increased frequenc

205 atabase of 13,664 MHD patients who underwent HCV antibody serology testing at least once during a 3-y

206 Subjects were identified from 1,454 HCV antibody-seropositive US veterans tested for HCV RNA

207 o three genotype 1a-derived HCV antigens and HCV antibody serotype were examined in chronically HCV i

208 Neutralizing breadth of HCV antibodies should be defined using viruses spanning

209 h an increased risk of LTFU after a positive HCV antibody test (adjusted risk ratio [aRR] = 1.41, 95%

210 nd HCV infection was assessed via a positive HCV antibody test and a positive HCV RNA test.

211 recommended testing sequence is to obtain an HCV antibody test and, when positive, perform an HCV RNA

212 xposure fail to receive the recommended anti-HCV antibody test at age >=18 months.

213 xposure fail to receive the recommended anti-HCV antibody test at age 18 months.

214 Screening with the HCV antibody test followed by the nucleic acid test for

215 s than two-thirds of persons with a positive HCV antibody test had a follow-up RNA test.

216 infection, one-third of whom had a negative HCV antibody test result at the time of the HCV RNA posi

217 ements and detectable HCV RNA, or a positive HCV antibody test result if HCV RNA measurements were no

218 ements and detectable HCV RNA, or a positive HCV antibody test result if HCV RNA measurements were no

219 viduals had a lower probability of having an HCV antibody test than white individuals (risk ratio, 0.

220 A total of 1549 participants received a HCV antibody test with 17% (264 of 1549) receiving a pos

221 e adjusted risk ratio (aRR) for receiving an HCV antibody test, and costs were estimated using activi

222 After a positive HCV antibody test, patients without TB had viremia testi

223 th having an RNA test after a first positive HCV antibody test.

224 for HCV RNA with the use of a more sensitive HCV-antibody test).

225 Among 11 267 patients, proportions of HCV antibody tested (52.5% in 2013-2014 vs 73.3% in 2015

226 associated with an increased odds of recent HCV antibody testing (4 studies; odds ratio (OR), 1.80;

227 Therefore, we suggest that the HCV antibody testing algorithm for the VITROS assay migh

228 57 [95% confidence interval, 2.32-2.85]) for HCV antibody testing and 1.62 (rate ratio, 1.62 [95% con

229 sly undiagnosed HCV disease, as suggested by HCV antibody testing and HCV polymerase chain reaction a

230 months), saliva was collected for anonymous HCV antibody testing and risk behavior data were obtaine

231 iate residents from 137 countries, underwent HCV antibody testing using the Elecsys Anti-HCV II elect

232 HCV antibody testing volumes increased 72% over the stud

233 Anti-HCV antibody testing was performed for 4582, or 90%, of

234 HCV antibody testing was performed on excess samples.

235 omeless shelters via mobile unit using rapid HCV antibody testing, followed by HCV-RNA testing in Mad

236 ces in achieving HCV cascade of care stages (HCV antibody testing, HCV infection [positive HCV RNA te

237 solicitation), evaluated hepatitis C virus (HCV) antibody testing, diagnosis, and costs for each of

238 l 2020, there were declines in the number of HCV antibody tests (37% reduction, P < .001), RNA tests

239 Over a one-month period, HCV antibody tests were conducted in 905 individuals wit

240 HCV antibody tests were performed by the enzyme-linked i

241 This antigen elicited anti-HCV antibodies that targeted conserved neutralizing epit

242 The pre-HIV infection HCV antibody titer was a predictor of the subsequent tit

243 he combined anti-core, anti-E1, and anti-NS4 HCV antibody titers in those with SVRs but not in those

244 A decline of hepatitis C virus (HCV) antibody titers (anti-HCV), ultimately resulting in

245 HCV-viraemic prevalence and HCV-antibody/viraemic incidence were measured using a st

246 HCV viremic prevalence and HCV antibody/viremic incidence were measured using a sta

247 HCV antibody was detected in 128 of 924 (14%; 95% confid

248 ce with either gradual or rapid loss of anti-HCV antibody was observed in four animals within 5 month

249 characterized by persistent HCV RNA and anti-HCV antibody was observed in two animals.

250 Age-standardized prevalence of HCV antibody was similar in NHANES 2007-2010 (1.5%) and

251 sing fasting glucose and medical history and HCV antibodies were assessed at baseline.

252 Using the HCV-LP ELISA, high-titer anti-HCV antibodies were detected in individuals infected wit

253 HCV antibodies were found in 12.1% of 207 syringes teste

254 HCV antibodies were measured from all HCV RNA-positive s

255 egative for human immunodeficiency virus and HCV antibodies were recruited into a prospective study i

256 IDUs <30 years old who tested negative for HCV antibody were enrolled in a prospective cohort.

257 t the proportion of patients with a positive HCV antibody who had a positive HCV RNA was 0.5 (95% con

258 Approximately 2% of U.S. adults have HCV antibodies, with the majority having chronic infecti

259 Fully implemented birth cohort screening for HCV antibody would have missed 36 of 128 (28%) of cases